Tolerance of anticoagulation in hereditary hemorrhagic telangiectasia
Despite being a hemorrhagic condition, patients with hereditary hemorrhagic telangiectasia (HHT) are at increased thromboembolic risk. We designed an observational retrospective cohort study of HHT patients who required anticoagulation therapy, described their indications and adverse events. From January 2006 until August 2019 28 out of 347 adult HHT patients received anticoagulant drugs for a median of 0.5  years (IQR 0.2–4.1). Median age was 64 years (IQR 51–70), all of the patients had epistaxis and at least one arteriovenous malformation. (Source: Thrombosis Research)
Source: Thrombosis Research - October 19, 2020 Category: Hematology Authors: Nicolas Tentoni, Martin I. Lapidus, Veronica A. Peuchot, Fernando J. Vazquez, Marcelo M. Serra Tags: Letter to the Editors-in-Chief Source Type: research

UK real-world experience of prescribing rivaroxaban for acute venous thromboembolism in obesity: Results from the FIRST registry
(Source: Thrombosis Research)
Source: Thrombosis Research - October 19, 2020 Category: Hematology Authors: V. Speed, J.P. Patel, L.N. Roberts, R.K. Patel, R. Arya, for the FIRST Registry Investigators Tags: Letter to the Editors-in-Chief Source Type: research

More precise dosing of acenocoumarol for better control in patients aged above 80 years, a randomised controlled pilot study
Many elderly patients are confined to treatment with vitamin K antagonists (VKA) instead of direct oral anticoagulants (DOACs). However, quality of VKA treatment declines with age. This might be caused by the lower dose requirements with increasing age, which result in relatively large day-by-day VKA dose differences. Therefore, more precise dosing with smaller dose increments might improve quality of VKA treatment in the elderly. (Source: Thrombosis Research)
Source: Thrombosis Research - October 16, 2020 Category: Hematology Authors: M. Piersma-Wichers, J.H.A. van Miert, N.J.G.M. Veeger, H.A.M. Kooistra, K. Meijer Tags: Letter to the Editors-in-Chief Source Type: research

Thrombotic Antiphospholipid Syndrome: a practical guide to diagnosis and management
Thrombotic antiphospholipid syndrome (APS) is characterised by venous, arterial or microvascular thrombosis in the context of persistently positive antiphospholipid antibodies (aPL). The diagnosis and management of thrombotic APS continues to prove challenging for clinicians. We provide a practical guide to the diagnosis of APS including who to test for aPL and which tests to do. We also consider clinical practice points on the management of venous, arterial and small vessel thrombosis, in the context of first and recurrent thrombotic events. (Source: Thrombosis Research)
Source: Thrombosis Research - October 15, 2020 Category: Hematology Authors: Zara Sayar, Rachel Moll, David Isenberg, Hannah Cohen Source Type: research

Twice- or Once-Daily Dosing of Direct Oral Anticoagulants, a systematic review and meta-analysis
AimThe direct oral anticoagulants (DOAC) have similar half-lives, but the dosing regimen varies between once daily (QD) or twice daily (BID). For some prescribers, the QD regimen improves compliance. Others prefer BID regimens to promote better stability of plasma concentrations, particularly in the event of missed doses. Limited level of evidence provides guidance about the best treatment strategy. The purpose of this study was to compare the treatment effect of QD vs. BID administration of DOACs in major orthopedic surgery (MOS), non-valvular atrial fibrillation (NVAF), venous thromboembolism (VTE), and acute coronary sy...
Source: Thrombosis Research - October 15, 2020 Category: Hematology Authors: S. Mainbourg, M. Cucherat, S. Provencher, L. Bertoletti, P. Nony, F. Gueyffier, P. Mismetti, C. Grange, I. Durieu, R. Kilo, S. Laporte, G. Grenet, J.-C. Lega, on behalf of META-EMBOL group Source Type: research

Long-term bleeding risk vs. mortality risk in acute coronary syndrome patients according to the 2019 ARC-HBR definition
(Source: Thrombosis Research)
Source: Thrombosis Research - October 15, 2020 Category: Hematology Authors: Alberto Cordero, David Escribano, Jos é Mª. García-Acuña, Moisés Rodriguez-Mañero, Rosa Agra-Bermejo, Vicente Bertomeu-González, Belén Cid, Belén Alvarez, Pilar Zuazola, José R. González-Juanatey Tags: Letter to the Editors-in-Chief Source Type: research

Determinants of plasma fibrin clot lysis measured using three different assays in healthy subjects
Several methods for measuring fibrinolytic capacity in plasma have been developed yielding frequently inconsistent results. We investigated which factors determine fibrinolytic capacity in three plasma-based assays. (Source: Thrombosis Research)
Source: Thrombosis Research - October 15, 2020 Category: Hematology Authors: Jakub Siudut, Teresa Iwaniec, Krzysztof Plens, Marlien Pieters, Anetta Undas Source Type: research

Impact of atrial fibrillation/flutter on the in-hospital mortality of surgical patients – results from the German nationwide cohort
To investigate the impact of atrial fibrillation/flutter (AF) on adverse in-hospital outcomes in hospitalized surgical patients. (Source: Thrombosis Research)
Source: Thrombosis Research - October 15, 2020 Category: Hematology Authors: Karsten Keller, Lukas Hobohm, Martin Engelhardt Source Type: research

COVID-19 associated coagulopathy: Thrombosis, hemorrhage and mortality rates with an escalated-dose Thromboprophylaxis strategy
As of September 19th, 2020, more than 30 million cases of novel coronavirus disease 2019 (COVID-19), the clinical syndrome caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, have been recorded, with more than 900,000 deaths worldwide and 200,000 in the United States, with a case fatality rate exceeding 3% [1]. (Source: Thrombosis Research)
Source: Thrombosis Research - October 14, 2020 Category: Hematology Authors: Molly M. Daughety, Andrew Morgan, Erin Frost, Chester Kao, Joyce Hwang, Rachel Tobin, Bhavik Patel, Matthew Fuller, Ian Welsby, Thomas L. Ortel Tags: Letter to the Editors-in-Chief Source Type: research

The prevalence of pulmonary embolism in patients with COVID-19 and respiratory decline: A three-setting comparison
The risk of pulmonary embolism (PE) in patients with Coronavirus Disease 2019 (COVID-19) is recognized. The prevalence of PE in patients with respiratory deterioration at the Emergency Department (ED), the regular ward, and the Intensive Care Unit (ICU) are not well-established. (Source: Thrombosis Research)
Source: Thrombosis Research - October 14, 2020 Category: Hematology Authors: Ren ée R.A.G. Brüggemann, Bart Spaetgens, Hester A. Gietema, Steffie H.A. Brouns, Patricia M. Stassen, Fabienne J. Magdelijns, Roger J. Rennenberg, Ronald M.A. Henry, Mark M.G. Mulder, Bas C.T. van Bussel, Ronny M. Schnabel, Iwan C.C. van der Horst, Joa Source Type: research

Incidence of thrombotic outcomes for patients hospitalized and discharged after COVID-19 infection
To the editor, (Source: Thrombosis Research)
Source: Thrombosis Research - October 14, 2020 Category: Hematology Authors: Alex Bourguignon, Camille Beaulieu, Wiam Belkaid, Antoine Desilets, Normand Blais Tags: Letter to the Editors-in-Chief Source Type: research

Corrigendum to “Rivaroxaban or apixaban in fragile patients with acute venous thromboembolism” [Thromb. Res. 193 (2020) 160–165]
The authors regret the inconvenience, but there is an error in the affiliation data of Patricia Beroiz MD, and the “Universidad Autónoma de Barcelona” is missing in her data. The correct affiliation data of Dra Beroiz is: (Source: Thrombosis Research)
Source: Thrombosis Research - October 13, 2020 Category: Hematology Authors: Javier Trujillo-Santos, Patricia Beroiz, Far ès Moustafa, Alicia Alonso, Estrella Morejon, Raquel López-Reyes, Ignacio Casado, José Antonio Porras, Katia Flores, Juan J. López-Núñez, Manuel Monreal, the RIETE Investigators Tags: Corrigendum Source Type: research

D-dimer measurement in COVID-19: Silver bullet or clinical distraction?
Coronavirus disease 2019 (COVID-19), the severe infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has now spread all over the world, infecting several millions of people and causing nearly 1 million casualties to date. According to our current understanding of this insidious pathology, the disease develops through a continuum of different phases [1]. The lower respiratory tract is primarily involved, with development of interstitial pneumonia, most often bilateral, and progression towards acute respiratory distress syndrome (ARDS) in a certain number of patients (i.e., between 5 and...
Source: Thrombosis Research - October 12, 2020 Category: Hematology Authors: Giuseppe Lippi, Emmanuel J. Favaloro Tags: Editorial Source Type: research

Serial block-face scanning electron microscopy: a provocative technique to define 3-dimensional ultrastructure of microvascular thrombosis 3D imaging of microvascular thrombi
(Source: Thrombosis Research)
Source: Thrombosis Research - October 12, 2020 Category: Hematology Authors: Justin A. Courson, Samuel D. Hanlon, Monica A. Bray, Fong W. Lam, Alan R. Burns, Rolando E. Rumbaut Tags: Letter to the Editors-in-Chief Source Type: research

Does high on-treatment platelet aggregability reflect poor individual response to clopidogrel?
On-treatment platelet aggregability represents the major form of functional assessment for patients treated with P2Y12 receptor antagonists, with “high” on-treatment platelet aggregability (HTPA) predicting thrombotic risk. However HTPA reflects a variable combination of pre-treatment hyperaggregability and poor response to P2Y12 antagonists. We have previously shown that integrity of platelet adenylate cyclase/cAMP signaling, assessed wi th PGE1, is a strong predictor of individual responses to clopidogrel. (Source: Thrombosis Research)
Source: Thrombosis Research - October 12, 2020 Category: Hematology Authors: B. Nooney Vivek, L. Hurst Nicola, Raffaele De Caterina, Y. Chirkov Yuliy, John D. Horowitz Source Type: research

Anticoagulation in COVID-19: Randomized trials should set the balance between excitement and evidence
(Source: Thrombosis Research)
Source: Thrombosis Research - October 8, 2020 Category: Hematology Authors: Behnood Bikdeli Source Type: research

More on clinical and computed tomography characteristics of COVID-19 associated acute pulmonary embolism
(Source: Thrombosis Research)
Source: Thrombosis Research - October 8, 2020 Category: Hematology Authors: L.F. van Dam, Kroft LJM, L.I. van der Wal, S.C. Cannegieter, J. Eikenboom, E. de Jonge, M.V. Huisman, F.A. Klok Tags: Letter to the Editors-in-Chief Source Type: research

Updated hospital associated venous thromboembolism outcomes with 90-days follow-up after hospitalisation for severe COVID-19 in two UK critical care units
(Source: Thrombosis Research)
Source: Thrombosis Research - October 8, 2020 Category: Hematology Authors: Andrew J. Doyle, Will Thomas, Andrew Retter, Martin Besser, Stephen MacDonald, Karen A. Breen, Michael J.R. Desborough, Beverley J. Hunt Tags: Letter to the Editors-in-Chief Source Type: research

Uninterrupted direct oral anticoagulant treatment during acute illness: Impact on clinical outcomes
Uninterrupted drug therapy during acute illness is often associated with pharmacokinetic and pharmacodynamic variations. Among warfarin treated patients, these changes are reflected in the INR. However, in the case of direct oral anticoagulants (DOACs), given that routine laboratory monitoring is not recommended, these changes may result in unforeseen thromboembolic or bleeding events. (Source: Thrombosis Research)
Source: Thrombosis Research - October 7, 2020 Category: Hematology Authors: Itai Gueta, Nadav Yehoshua Shacham, Noa Markovits, Hillel Halkin, Ronen Loebstein Source Type: research

Lemierre syndrome: Current evidence and rationale of the Bacteria-associated thrombosis, thrombophlebitis and LEmierre syndrome registry (BATTLE)
Lemierre syndrome is a rare but potentially fatal condition characterized by septic thrombophlebitis of the head and neck district, preferentially affecting adolescents and young adults and manifesting as a complication of a local bacterial infection – typically, a pharyngotonsillitis or an abscess. It is historically associated with the Gram-negative anaerobic rod Fusobacterium necrophorum and with thrombophlebitis of the internal jugular vein. However, its definition has never been firmly established, and its spectrum within the continuum of bacteria-associated thrombophlebitis may be larger than what presumed so f...
Source: Thrombosis Research - October 7, 2020 Category: Hematology Authors: Valerio Luca, Gabriele Corsi, Tim Sebastian, Stefano Barco Source Type: research

DOAC in intermediate-high risk PE
The safety and efficacy of direct oral anticoagulants (DOACs) in intermediate-high risk pulmonary embolism (PE) are unknown. The aims of the present study were to describe outcomes of patients receiving early apixaban or rivaroxaban prescription rather the recommended delayed prescription strategy. (Source: Thrombosis Research)
Source: Thrombosis Research - October 7, 2020 Category: Hematology Authors: Romain Chopard, Marc Badoz, Charly Eveno, Fiona Ecarnot, Nicolas Falvo, Elsa Kalbacher, Gilles Capellier, Benoit Guillon, Fran çois Schiele, Nicolas Meneveau Source Type: research

VTE risk stratification in patients with Cancer
Risk assessment models are used to stratify cancer patients according to their underlying risk of VTE. The CATS score has been shown to enhance VTE risk stratification as compared to the modified Khorana score by incorporating d-dimer and soluble p-selectin measurements. Our aim was to evaluate the performance of the CATS score with respect to VTE risk stratification. (Source: Thrombosis Research)
Source: Thrombosis Research - October 7, 2020 Category: Hematology Authors: Joseph R. Shaw, Vaibhav Kumar, Ranjeeta Mallick, Marc Carrier, Anton Ilich, Nigel S. Key, Philip Wells Source Type: research

Why thromboembolism occurs in some patients with thrombocytopenia and treatment strategies
Platelets play such an important role in the process of thrombosis that patients with thrombocytopenia generally have an increased risk of bleeding. However, abnormal thrombotic events can sometimes occur in patients with thrombocytopenia, which is unusual and inexplicable. The treatments for thrombocytopenia and thromboembolism are usually contradictory. This review introduces the mechanisms of thromboembolism in patients with different types of thrombocytopenia and outlines treatment recommendations for the prevention and treatment of thrombosis. (Source: Thrombosis Research)
Source: Thrombosis Research - October 7, 2020 Category: Hematology Authors: Xiaorong Han, Cheng Li, Shuai Zhang, Xiaojie Hou, Zhongbo Chen, Jin Zhang, Ying Zhang, JianSun, Yonggang Wang Source Type: research

Proteomics reveals region-specific hemostatic alterations in response to mechanical ventilation in a preterm lamb model of lung injury
Preterm infants often require assisted ventilation, however ventilation when applied to the immature lung can initiate ventilator-induced lung injury (VILI). The biotrauma which underscores VILI is largely undefined, and is likely to involve vascular injury responses, including hemostasis. We aimed to use a ventilated, preterm lamb model to: (1) characterize regional alterations in hemostatic mediators within the lung and (2) assess the functional impact of protein alterations on hemostasis by analyzing temporal thrombin generation. (Source: Thrombosis Research)
Source: Thrombosis Research - October 7, 2020 Category: Hematology Authors: Christine Schmid, Vera Ignjatovic, Boyuan Pang, Shuai Nie, Nicholas A. Williamson, David G. Tingay, Prue M. Pereira-Fantini Source Type: research

Sub-segmental pulmonary emboli as a marker of CT-pulmonary angiogram overuse in a single-center retrospective cohort study: A dimer a dozen?
Recently, computed tomography pulmonary angiography (CTPA) has emerged as the first line modality for the diagnosis of pulmonary embolism (PE) as it is fast, reliable and widely available [1]. However, with increasing use of CTPA, there has been an associated increase in the incidence of PE with no significant change in mortality [2]. Overuse of CTPA leads to unnecessary radiation and contrast exposure, increased costs, as well as incidental findings, raising the question of over-diagnosis of clinically insignificant PEs conferring a major burden on both patients and healthcare system (2,3). (Source: Thrombosis Research)
Source: Thrombosis Research - October 7, 2020 Category: Hematology Authors: Lindsey Gerstein, Maral Koolian, Blair C. Schwartz Tags: Letter to the Editors-in-Chief Source Type: research

Venous and arterial thromboembolic events with immune checkpoint inhibitors: A systematic review
Venous (VTEs) and arterial thromboembolic events (ATEs) are causes of morbidity, disability, mortality, and increase in treatment costs in cancer patients. The risk associated with immune checkpoint inhibitors (ICIs) has not yet been clarified. The primary objective of this systematic review was to evaluate the incidence of VTEs and ATEs in patients treated with ICIs as single agents or in combination with other treatments. (Source: Thrombosis Research)
Source: Thrombosis Research - October 7, 2020 Category: Hematology Authors: Cinzia Solinas, Luca Saba, Paolo Sganzerla, Fausto Petrelli Tags: Short review Source Type: research

Anti-Xa Monitoring improves Low-Molecular-Weight Heparin Effectiveness in patients with SARS-CoV-2 infection
(Source: Thrombosis Research)
Source: Thrombosis Research - October 7, 2020 Category: Hematology Authors: Mattia Trunfio, Elena Salvador, Daniela Cabodi, Letizia Marinaro, Chiara Alcantarini, Alberto Gaviraghi, Alice Trentalange, Filippo Lipani, Savino Sciascia, Dario Roccatello, Stefano Bonora, Giovanni Di Perri, Andrea Calcagno, for the e-COVID Study group Tags: Letter to the Editors-in-Chief Source Type: research

Increased D-dimer predicts the risk of cancer-associated recurrent venous thromboembolism and venous thromboembolism: A systematic review and meta-analysis
Thrombosis is four to six times higher in cancer patients compared to non-cancer patients and is the second leading cause of death in cancer patients [1,2]. Therefore, it is necessary to predict and guide treatments for cancer-associated VTE and recurrent VTE by using biomarkers or predictive models. The Khorana score, a predictive model that combines three biomarkers, including platelet count, hemoglobin and white blood cell count, with cancer type, is widely used to assess the increased risk of cancer-related thrombosis [3]. (Source: Thrombosis Research)
Source: Thrombosis Research - September 26, 2020 Category: Hematology Authors: Meng Yang, Jiaqian Qi, Yaqiong Tang, Depei Wu, Yue Han Tags: Letter to the Editors-in-Chief Source Type: research

Updated meta-analysis on the efficacy of genotype-guided antiplatelet therapy versus standard therapy for patients undergoing PCI
We read with great interest the systematic review and meta-analysis titled “Genotype-guided antiplatelet therapy compared with standard therapy for patients with acute coronary syndromes or undergoing percutaneous coronary intervention: A systematic review and meta-analysis” [1] by Wang et al. This meta-analysis included a total of 4859 from seven randomized controlled trials (RCTs) and demonstrated that the genotype-guided antiplatelet therapy may reduce the risk of myocardial infarction (MI) and stent thrombosis compared with standard treatment. (Source: Thrombosis Research)
Source: Thrombosis Research - September 25, 2020 Category: Hematology Authors: Yuki Sahashi, Toshiki Kuno, Sripal Bangalore Tags: Letter to the Editors-in-Chief Source Type: research

Thrombin generation in subjects with lupus anticoagulant without prior thrombosis or gestational morbidities
Lupus anticoagulant (LA) can be a cause of thrombosis and/or pregnancy morbidities, producing antiphospholipid syndrome (APS). An increase in thrombin generation (TG) is correlated with prothrombotic status. Several changes in TG-derived parameters have been reported in APS patients. (Source: Thrombosis Research)
Source: Thrombosis Research - September 24, 2020 Category: Hematology Authors: Diego Velasco-Rodr íguez, Rosa Vidal Laso, Aránzazu García-Raso, Ignacio Mahíllo-Fernández, Karina Guzmán-López, Sara Martín-Herrero, Elena Jiménez Barral, María del Carmen Vegas-Sánchez, María José Martínez-Becerra, Reyes de la Plaza, Luisa Tags: Full Length Article Source Type: research

Real-life evaluation of an automated immunoassay for diagnosis of heparin-induced thrombocytopenia
Heparin-induced thrombocytopenia (HIT) is caused by IgG antibodies against platelet factor 4 (PF4)/heparin (H) complexes. Typical clinical features include a fall in platelet count by more than 50% and/or new thromboembolic complications occurring between days 5 and 10 after exposure to unfractionated heparin (UFH) or low molecular heparin (LMWH). Two different types of laboratory assays are available; immunoassays, which detect anti-PF4/H antibodies; and functional assays, which identify the subgroup of platelet-activating, and thereby potentially pathogenic, heparin-dependent antibodies [1]. (Source: Thrombosis Research)
Source: Thrombosis Research - September 24, 2020 Category: Hematology Authors: Karina Althaus, Antje Westphal, Ulrike Strobel, Tamam Bakchoul, Andreas Greinacher Tags: Letter to the Editors-in-Chief Source Type: research

Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies
Microvascular and macrovascular thrombotic events are among the hallmarks of coronavirus disease 2019 (COVID-19). Furthermore, the exuberant immune response is considered an important driver of pulmonary and extrapulmonary manifestations of COVID-19. The optimal management strategy to prevent thrombosis in critically-ill patients with COVID-19 remains unknown. (Source: Thrombosis Research)
Source: Thrombosis Research - September 22, 2020 Category: Hematology Authors: Behnood Bikdeli, Azita H. Talasaz, Farid Rashidi, Babak Sharif-Kashani, Mohsen Farrokhpour, Hooman Bakhshandeh, Hashem Sezavar, Ali Dabbagh, Mohammad Taghi Beigmohammadi, Pooya Payandemehr, Mahdi Yadollahzadeh, Taghi Riahi, Hossein Khalili, Sepehr Jamalkh Tags: Full Length Article Source Type: research

Intensity of anticoagulation and survival in patients hospitalized with COVID-19 pneumonia
SARS-CoV-2 infection has noted derangements in coagulation markers along with significant thrombotic complications. Post-mortem examinations show severe endothelial injury and widespread thrombotic microangiopathy in the pulmonary vasculature. Early reports describing the use of prophylactic anticoagulation demonstrated improved survival, leading to the adoption of prophylactic and therapeutic anticoagulation guided by D-dimer levels. The clinical usefulness of D-dimer values, trends, and more intensive anticoagulation remains an area of clinical interest. (Source: Thrombosis Research)
Source: Thrombosis Research - September 21, 2020 Category: Hematology Authors: Andrew Hsu, Yuchen Liu, Adam S. Zayac, Adam J. Olszewski, John L. Reagan Tags: Letter to the Editors-in-Chief Source Type: research

A new hybrid immunocapture bioassay with improved reproducibility to measure tissue factor-dependent procoagulant activity of microvesicles from body fluids
The procoagulant activity of tissue factor-bearing microvesicles (MV-TF) has been associated with the risk of developing venous thrombosis in cancer patients. However, MV-TF assays are limited either by i) a lack of specificity, ii) a low sensitivity, or iii) a lack of repeatability when high-speed centrifugation (HS-C) is used to isolate MV. Therefore, our objective was to develop a new hybrid “capture-bioassay” with improved reproducibility combining MV immunocapture from biofluids and measurement of their TF activity. (Source: Thrombosis Research)
Source: Thrombosis Research - September 19, 2020 Category: Hematology Authors: Corentin Franco, Romaric Lacroix, Loris Vallier, Coralie Judicone, Tarik Bouriche, Sophie Laroumagne, Philippe Astoul, Francoise Dignat-George, Philippe Poncelet Tags: Full Length Article Source Type: research

Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID)
Coronavirus disease 2019 (COVID-19) causes a hypercoagulable state. Several autopsy studies have found microthrombi in pulmonary circulation. (Source: Thrombosis Research)
Source: Thrombosis Research - September 19, 2020 Category: Hematology Authors: Anna Cristina Bertoldi Lemos, Douglas Alexandre do Esp írito Santo, Maísa Cabetti Salvetti, Renato Noffs Gilio, Lucas Barbosa Agra, Antonio Pazin-Filho, Carlos Henrique Miranda Tags: Full Length Article Source Type: research

Outcome of intracranial bleeding managed with prothrombin complex concentrate in patients on direct factor Xa inhibitors or vitamin K antagonists
Intracranial hemorrhage (ICH) is the most feared complication of anticoagulation with a high mortality and morbidity. Before registration of a specific reversal agent for factor Xa inhibitors (FXa-I), international guidelines recommended prothrombin complex concentrate (PCC), which also is the specific reversal agent for vitamin K antagonists (VKA). In two contemporary cohorts, we compared clinical outcomes between patients with FXa-I and VKA related ICH treated with PCC between 2014 and 2018. Primary outcome was effective hemostasis after 24  h, according to the International Society of Thrombosis and Hemostasis definit...
Source: Thrombosis Research - September 19, 2020 Category: Hematology Authors: Roisin Bavalia, Rahat Abdoellakhan, Ludo F. Beenen, M.P.A. Brekelmans, Renske H. Olie, Hugo ten Cate, Menno V. Huisman, Marieke Kruip, Saskia Middeldorp, Karina Meijer, Barbara A. Hutten, Michiel Coppens Tags: Full Length Article Source Type: research

The risk factors for perioperative venous thromboembolism in patients with gynecological malignancies: A meta-analysis
This meta-analysis aimed to identify the risk factors for venous thromboembolism (VTE) in patients with gynecological malignancy during the perioperative period. (Source: Thrombosis Research)
Source: Thrombosis Research - September 17, 2020 Category: Hematology Authors: Se-Ge Ma, Juan Hu, Yan Huang Tags: Review Article Source Type: research

The hazard of fondaparinux in non-critically ill patients with COVID-19: Retrospective controlled study versus enoxaparin
COVID-19 (acronym of COronaVIrus Disease 2019) is an infectious respiratory disease, responsible for a worldwide pandemic, with a high rate of venous and arterial thrombotic complications. These complications have recently been reported to occur in patients with COVID-19 disease regardless of the use of prophylactic doses of low-molecular-weight heparin (LMWH) [1,2]. Although their incidence is higher in the most severe patients, it has been reported to be substantial also in those with less severe disease [1,3,4]. (Source: Thrombosis Research)
Source: Thrombosis Research - September 16, 2020 Category: Hematology Authors: Paolo Prandoni, Anna Maria Cattelan, Laura Carrozzi, Lucia Leone, Lucia Filippi, Egidio De Gaudenzi, Sabina Villalta, Raffaele Pesavento, for the FONDACOVIT Investigators [all in Italy] Tags: Letter to the Editors-in-Chief Source Type: research

Sex-related characteristics of cerebral vein thrombosis: A secondary analysis of a multicenter international cohort study
Sex differences have been reported in the epidemiology, clinical presentation and outcomes of cardiovascular disease (CVD) [1]. Despite the availability of evidence associated with sex-related differences for most CVD, evidence in patients with cerebral vein thrombosis (CVT) is limited and controversial. Cerebral vein thrombosis is a venous thrombosis occurring in an unusual site and is more common in females than in males, possibly because of the role of female-specific risk factors [2]. Also, there is limited evidence available in the literature on differences between males and females clinical history of CVT. (Source: Thrombosis Research)
Source: Thrombosis Research - September 16, 2020 Category: Hematology Authors: Porceddu Enrica, Rezoagli Emanuele, Poli Daniela, Magliocca Aurora, Scoditti Umberto, Di Minno Matteo Nicola Dario, De Stefano Valerio, Siragusa Sergio, Ageno Walter, Dentali Francesco, for the CEVETIS (CErebral VEin Thrombosis International Study) Invest Tags: Letter to the Editors-in-Chief Source Type: research

D-dimer cut-off points and risk of venous thromboembolism in adult hospitalized patients with COVID-19
The novel coronavirus disease 2019 (COVID-19) pandemic has led to more than 24 million confirmed cases and over 820,000 deaths worldwide as of late August 2020. Early observational studies reported high rates of venous thromboembolism (VTE) in critically ill patients with COVID-19 [1]. A recent meta-analysis reported an incidence of 26% for VTE among 3487 patients from 30 studies based on very low-quality evidence due to heterogeneity and risk of bias [2]. Furthermore, studies have reported that elevated D-dimer values in COVID-19 are associated with a higher risk of VTE, mechanical ventilation, and mortality [3 –5]....
Source: Thrombosis Research - September 15, 2020 Category: Hematology Authors: Justin J. Choi, Graham T. Wehmeyer, Han A. Li, Mark N. Alshak, Musarrat Nahid, Mangala Rajan, Bethina Liu, Emma M. Schatoff, Rahmi Elahjji, Youmna Abdelghany, Debra D'Angelo, Daniel Crossman, Arthur T. Evans, Peter Steel, Laura C. Pinheiro, Parag Goyal, M Tags: Letter to the Editors-in-Chief Source Type: research

Risk of post-thrombotic syndrome after deep vein thrombosis treated with rivaroxaban versus vitamin-K antagonists: A systematic review and meta-analysis
Post-thrombotic syndrome (PTS) is a burdensome long-term complication of deep vein thrombosis (DVT). Recent studies have suggested that rivaroxaban may reduce PTS events compared to vitamin-K antagonists (VKAs). We, therefore, systematically reviewed available literature that compared rivaroxaban versus VKAs on the risk of PTS. (Source: Thrombosis Research)
Source: Thrombosis Research - September 15, 2020 Category: Hematology Authors: Ruihao Li, Manqiu Yuan, Junning Cheng, Shixiong Yu, Wei Wei, Wenlong Fu, Paolo Prandoni, Yikuan Chen Tags: Review Article Source Type: research

Validation of the PLASMIC score for predicting ADAMTS13 activity < 10% in patients with suspected thrombotic thrombocytopenic purpura in Alberta, Canada
Thrombotic thrombocytopenic purpura (TTP) is a life-threatening thrombotic microangiopathy (TMA) that requires prompt plasma exchange. Clinical prediction tools may facilitate decision-making in institutions with delayed turnaround time or limited access to ADAMTS13 assays. The PLASMIC score and Bentley score have been shown to predict severe ADAMTS13 deficiency with excellent sensitivity and specificity. (Source: Thrombosis Research)
Source: Thrombosis Research - September 14, 2020 Category: Hematology Authors: Chris Wynick, Joanne Britto, Daniel Sawler, Arabesque Parker, Mohammad Karkhaneh, M. Dawn Goodyear, Haowei (Linda) Sun Tags: Full Length Article Source Type: research

COVID-19 coagulopathy and thrombosis: Analysis of hospital protocols in response to the rapidly evolving pandemic
As the Coronavirus disease 2019 (COVID-19) pandemic spread to the US, so too did descriptions of an associated coagulopathy and thrombotic complications. Hospitals created institutional protocols for inpatient management of COVID-19 coagulopathy and thrombosis in response to this developing data. We collected and analyzed protocols from 21 US academic medical centers developed between January and May 2020. We found greatest consensus on recommendations for heparin-based pharmacologic venous thromboembolism (VTE) prophylaxis in COVID-19 patients without contraindications. (Source: Thrombosis Research)
Source: Thrombosis Research - September 14, 2020 Category: Hematology Authors: Anna L. Parks, Andrew D. Auerbach, Jeffrey L. Schnipper, James E. Anstey, David G. Sterken, Todd E.H. Hecht, Margaret C. Fang, the Hospital Medicine Reengineering Network (HOMERuN) Tags: Letter to the Editors-in-Chief Source Type: research

High plasma levels of soluble P-Selectin and Factor VIII predict venous thromboembolism in non-small cell lung cancer patients: The Thrombo-Nsclc risk score
Venous thromboembolism (VTE) is common in non-small cell lung cancer (NSCLC) patients undergoing systemic chemotherapy. The usefulness of Khorana score (KRS) to predict risk in lung cancer patients is limited, and the identification of patients who would benefit most from thromboprophylaxis is challenging. We aimed to identify variables whose values before chemotherapy helped in predicting VTE occurrence, and build a model to assess VTE risk. (Source: Thrombosis Research)
Source: Thrombosis Research - September 14, 2020 Category: Hematology Authors: Victoria E. Castell ón Rubio, Pedro Pérez Segura, Andrés J. Muñoz Martin A, Antonio López Farré, Liliana Canosa Ruiz, José A. Lorente Acosta Tags: Full Length Article Source Type: research

Biomarkers for the prediction of venous thromboembolism in critically ill COVID-19 patients
Venous thromboembolism (VTE) is a frequent complication in critically ill patients with coronavirus disease 2019 (COVID-19) and is associated with mortality. Early diagnosis and treatment of VTE is warranted. (Source: Thrombosis Research)
Source: Thrombosis Research - September 13, 2020 Category: Hematology Authors: Romein W.G. Dujardin, Bashar N. Hilderink, Wolmet E. Haksteen, S. Middeldorp, Alexander P.J. Vlaar, J. Thachil, Marcella C.A. M üller, Nicole P. Juffermans Tags: Full Length Article Source Type: research

Perspectives of patients and health professionals on important factors influencing rehabilitation following acute pulmonary embolism: A multi-method study
International guidelines on pulmonary embolism (PE) management and rehabilitation have recently been published. However, the contained recommendation about an efficient follow-up strategy after PE is difficult for health care professionals to implement because limited research exists about what strategies are efficient. (Source: Thrombosis Research)
Source: Thrombosis Research - September 12, 2020 Category: Hematology Authors: Nanna Rolving, Jannie Rhod Bloch-Nielsen, Barbara Christina Brocki, Jane Andreasen Tags: Full Length Article Source Type: research

Venous thromboembolism and bleeding in critically ill COVID-19 patients treated with higher than standard low molecular weight heparin doses and aspirin: A call to action
Critically ill COVID-19 patients have a clear pattern of inflammation and hypercoagulable state. The main aim of the study was to evaluate the outcome of severe COVID-19 patients basing on prothrombotic risk factors (i.e. D-dimer). We also evaluated the impact of different doses of low molecular weight heparin (LMWH) on incidence of major bleedings. (Source: Thrombosis Research)
Source: Thrombosis Research - September 12, 2020 Category: Hematology Authors: Vittorio Pavoni, Lara Gianesello, Maddalena Pazzi, Caterina Stera, Tommaso Meconi, Francesca Covani Frigieri Tags: Full Length Article Source Type: research

Clotting abnormalities in critically ill COVID-19 patients are inconsistent with overt disseminated intravascular coagulation
The SARS-CoV-2 is a coronavirus causing a human infection designated as COVID-19 by the World Health Organization. Up to 5% of symptomatic patients are admitted to intensive care unit (ICU) for acute respiratory distress syndrome (ARDS), sepsis and multiple organ failure. Clotting abnormalities have been documented in COVID-19 patients [1], eventually culminating in DIC in patients with poor prognosis [2]. However, the occurrence of consumption coagulopathy has been questioned by some reports [3,4]. (Source: Thrombosis Research)
Source: Thrombosis Research - September 11, 2020 Category: Hematology Authors: Domenico Paparella, Mario Colucci, Enrico Squiccimarro, Pasquale Raimondo, Federica De Palma, Prudenza Ranieri, Maria Addolorata Mariggi ò, Salvatore Grasso Tags: Letter to the Editors-in-Chief Source Type: research

ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3  months
The objective of this analysis of the ongoing ETNA-VTE Europe study was to assess the real-world benefits and risks of edoxaban during the first 3  months of treatment, the highest risk period for further VTE events. (Source: Thrombosis Research)
Source: Thrombosis Research - September 10, 2020 Category: Hematology Authors: Giancarlo Agnelli, Ulrich Hoffmann, Philippe Hainaut, Sean Gaine, Cihan Ay, Michiel Coppens, Marc Schindewolf, David Jimenez, Bernd Br üggenjürgen, Pierre Levy, Petra Laeis, Eva-Maria Fronk, Wolfgang Zierhut, Thomas Malzer, Marius Constantin Manu, Paul- Tags: Full Length Article Source Type: research

Aspirin related platelet reactivity as a determinant of ten year survival in high risk non-ST segment elevation myocardial infarction (NSTEMI) patients
Aspirin forms a cornerstone of management in patients with established cardiovascular disease (CVD). Despite proven efficacy, variability of aspirin response has long been recognised, with early studies suggesting rates of high on treatment platelet reactivity (HTPR) as ranging between 5 and 45%. Whether aspirin responsiveness relates to long-term prognosis in patients with CVD is unknown. (Source: Thrombosis Research)
Source: Thrombosis Research - September 9, 2020 Category: Hematology Authors: Nazish Khan, Mamas A. Mamas, Alexandra Moss, Diana A. Gorog, Peter Nightingale, Angel Armesilla, Andrew Smallwood, Shahzad Munir, Saib Khogali, Ben Wrigley, James M. Cotton Tags: Letter to the Editors-in-Chief Source Type: research